SCHEMBL4042647

SCHEMBL4042647

COc1cc(Nc2nc(N)n(-c3nc4ccccc4s3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.51
AXL P30530 2/20 0.47
PIK3CG P48736 1/20 0.47
SRC P12931 3/20 0.45
ZAP70 P43403 3/20 0.45
SYK P43405 3/20 0.45
KDR P35968 1/20 0.43
FLT3 P36888 3/20 0.42
CDK2 P24941 3/20 0.42
CDK4 P11802 2/20 0.42
GSK3B P49841 2/20 0.41
STK16 O75716 1/20 0.41
CLK1 P49759 1/20 0.41
CLK2 P49760 1/20 0.41
CLK3 P49761 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043057 0.90 BACE1 (0.58) BACE1AXLFLT3MEN1MAPK1
SCHEMBL4040816 0.86 BACE1 (0.55) BACE1AXLPIK3CGSRCZAP70
SCHEMBL4043414 0.86 BACE1 (0.49) BACE1AXLPIK3CGSRCZAP70
SCHEMBL12780844 0.84 BACE1 (0.56) BACE1AXLFLT3MEN1MAPK1
SCHEMBL12780837 0.83 BACE1 (0.67) BACE1AXLFLT3MEN1MAPK1
SCHEMBL12780839 0.81 FLT3 (0.66) BACE1AXLFLT3MEN1MAPK1
SCHEMBL12780127 0.80 SRC (0.56) BACE1AXLSRCZAP70SYK
SCHEMBL4039114 0.79 SRC (0.56) BACE1AXLSRCZAP70SYK
SCHEMBL4038868 0.79 BACE1 (0.56) BACE1AXLFLT3MEN1MAPK1
SCHEMBL4045177 0.79 FLT3 (0.66) BACE1AXLFLT3MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885AXL 762/4885PIK3CG 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.